Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer

Description

To estimate the MTD(s) and/ or RP2D of LEE011 in combination with everolimus + exemestane, and LEE011 in combination with exemestane, and to characterize the safety and tolerability of the combinations of everolimus + exemestane ± LEE011 and LEE011 + exemestane in patients with ER+ HER2- advanced breast cancer

Study Start Date

September 2013

Estimated Completion Date

November 2016

Interventions

  • Drug: LEE011
  • Drug: Everolimus
  • Drug: Exemestane

Specialties

  • Obstetrics & Gynecology: Breast,Clinical Pharmacology
  • Oncology: Breast,Pharmacology/Therapy
  • Pharmacy: Chemotherapy/Oncology,Drug Trials

MeSH Terms

  • Breast Cancer
  • Breast Neoplasms
  • Everolimus
  • Exemestane
  • LEE011

Study ID

Novartis -- CLEE011X2106

Status

Unknown

Trial ID

NCT01857193

Study Type

Interventional

Trial Phase

Phase 1/Phase 2

Enrollment Quota

142

Sponsor

Novartis

Inclusion Criteria

  • Adult women (? 18 years of age) with metastatic or locally advanced breast cancer not amenable to curative treatment by surgery or radiotherapy
  • Histological or cytological confirmation of estrogen-receptor positive (ER+) breast cancer
  • A representative tumor specimen must be available for molecular testing. An archival tumor sample may be submitted
  • if one is not available, a newly obtained tumor specimen must be submitted instead
  • Postmenopausal women. Postmenopausal status is defined either by:
  • Age ? 18 with prior bilateral oophorectomy
  • Age ? 60 years
  • Age <60 years with amenorrhea for at least 12 months and both follicle-stimulating hormone (FSH) and estradiol levels are in postmenopausal range (according to the local laboratory)
  • Recurrence while on, or within 12 months of end of adjuvant treatment with letrozole or anastrozole, or
  • Progression while on, or within one month of end of letrozole or anastrozole treatment for locally advanced or metastatic breast cancer.
  • Patients must have:
  • Measurable disease*: At least one lesion that can be accurately measured in at least one dimension ? 20 mm with conventional imaging techniques or ? 10 mm with spiral CT or MRI or
  • Bone lesions: lytic or mixed (lytic + sclerotic) in the absence of measurable disease as defined above.
  • ECOG Performance Status 0-1.
  • Exception for Phase Ib patients: measurable disease is not required

Exclusion Criteria

  • Her2-overexpressing patients by local laboratory testing (IHC 3+ staining or in situ hybridization positive).
  • Patients who received more than one chemotherapy line for advanced breast cancer.
  • Previous treatment with CDK4/6 inhibitors, exemestane or mTOR inhibitors*.
  • History of active or symptomatic brain or other CNS metastases.
  • Impaired cardiac function or clinically significant cardiac diseases, including any of the following:
  • Left ventricular ejection fraction (LVEF) < 45% or less than the institution lower limit of normal as determined by multiple gated acquisition scan (MUGA) or echocardiogram (ECHO)
  • Congenital long QT syndrome or family history of unexpected sudden cardiac death
  • QT corrected with Fredericia's (QTcF) >470 ms for females on screening ECG
  • Any other clinically significant heart disease such as angina pectoris, resting bradycardia, left bundle branch block, ventricular tachyarrhythmia, unstable atrial fibrillation, Right bundle branch block with left anterior hemiblock (bifascicular block), acute myocardial infarction or any heart disease that requires the use of a cardiac pacemaker or implantable cardioverter defibrillator ? 3 months prior to starting study drug.
  • Patients who are currently receiving treatment with agents that are known to cause QTc prolongation in humans.
  • Patients who are currently receiving treatment (within five days prior to randomization) with agents that are metabolized predominantly through CYP3A4 and that have a narrow therapeutic window. Agents that are known strong inducers or inhibitors CYP3A4 are prohibited (Refer to Appendix 4) * Exceptions for Phase Ib patients: 1. Patients who received more than two prior lines of chemotherapy are eligible 2. Patients who received CDK4/6 inhibitors, exemestane or mTOR inhibitors are eligible

Gender

Female

Ages

18 Years and older

Accepts Healthy Volunteers

No

Study Locations and Contact Information (3)

Study Location Distance Name Phone Email
Massachusetts General Hospital Onc Dept - Boston, Massachusetts 2.8 miles Jacqueline M Lusk 617-643-2208 jmlusk@mgh.harvard.edu
Karmanos Cancer Institute Dept of Onc - Detroit, Michigan 611.5 miles Barbara the Ivers +1 313 576 8096 iversb@karmanos.org
Memorial Sloan Kettering Cancer Center Oncology Dept - NY, New York 2,593.7 miles Alan Lau 646-888-5341 laura1@mskcc.org

ClinicalTrialsLocator.com provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from ClinicalTrials.gov. This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.